Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 3/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 4/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23584564 | 1.00 | PRMT5 (0.38) | PRMT5WDR77POLBNAMPTCNR2 | |
| SCHEMBL22435076 | 0.90 | PRMT5 (0.36) | PRMT5WDR77POLBNAMPTCNR2 | |
| SCHEMBL19344405 | 0.89 | PRMT5 (0.49) | PRMT5WDR77NAMPTCNR2MEN1 | |
| SCHEMBL19344047 | 0.88 | PRMT5 (0.48) | PRMT5WDR77MEN1KMT2AALDH1A1 | |
| SCHEMBL19344252 | 0.87 | PRMT5 (0.47) | PRMT5WDR77 | |
| SCHEMBL19344013 | 0.86 | PRMT5 (0.34) | PRMT5WDR77NAMPTCNR2OPRD1 | |
| SCHEMBL19343823 | 0.86 | PRMT5 (0.48) | PRMT5WDR77 | |
| SCHEMBL19344424 | 0.85 | PRMT5 (0.39) | PRMT5WDR77NAMPTCNR2CNR1 | |
| SCHEMBL19344250 | 0.85 | PRMT5 (0.44) | PRMT5WDR77 | |
| SCHEMBL19344049 | 0.83 | PRMT5 (0.46) | PRMT5WDR77MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
| WO-2017153186-A1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 133/4885POLB 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.